Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 16/20 | 0.89 |
| ▸ | ATP1B1 | P05026 | 16/20 | 0.89 |
| ▸ | ATP1B2 | P14415 | 16/20 | 0.89 |
| ▸ | ATP1A2 | P50993 | 16/20 | 0.89 |
| ▸ | ATP1B3 | P54709 | 16/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | TP53 | P04637 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.89 |
| ▸ | GLA | P06280 | 1/20 | 0.89 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.89 |
| ▸ | STAT3 | P40763 | 1/20 | 0.89 |
| ▸ | RECQL | P46063 | 1/20 | 0.89 |
| ▸ | RAB9A | P51151 | 1/20 | 0.89 |
| ▸ | RORC | P51449 | 1/20 | 0.89 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.89 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.89 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.89 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.89 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metildigoxin SCHEMBL2518178 | 1.00 | ATP1A1 (0.89) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Metildigoxin SCHEMBL43349 | 1.00 | ATP1A1 (0.89) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Metildigoxin SCHEMBL12841143 | 1.00 | ATP1A1 (0.89) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Metildigoxin SCHEMBL6598684 | 0.97 | ATP1A1 (0.94) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL8200838 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13354340 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL16144399 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL22904197 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL15959376 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL12841137 | 0.94 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101600-B2 | Compounds as RORγt modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140066391-A1 | STEROID COMPOUNDS AS RORyt MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-03-06 | — | — | US | disclosed |
| US-20130065842-A1 | COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066391-A1 | STEROID COMPOUNDS AS RORyt MODULATORS AND USES THEREOF | RORB, RORA, RORC | ATP1A1 3882/4885ATP1B1 3541/4885ATP1B2 4090/4885 |
| US-20130065842-A1 | COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | RORC, RORB, RORA | ATP1A1 4145/4885ATP1B1 4378/4885ATP1B2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.